Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Risk Factors and Different Therapeutic Patterns of Late-Onset Hemorrhagic Cystitis after Haploidentical Allogeneic Stem Cell Transplantation

Blood (2019) 134 (Supplement_1): 3261.

https://doi.org/10.1182/blood-2019-126230

Published: 2019

Journal Articles

Risk Factors of BK Virus Cystitis in Haematopoietic Stem Cell Transplantation-a Retrospective Monocentric Study

Eléonore Kaphan, Raphaele Germi, Martin Carre, Claude-Eric Bulabois, MD, Sebastien Bailly, Jean-Yves Cahn, MD, Anne Thiebaut-Bertrand

Blood (2018) 132 (Supplement 1): 3361.

https://doi.org/10.1182/blood-2018-99-115321

Published: 2018

Journal Articles

Intravesicular Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis (BKV-HC) Following Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Graham Tooker, Ashraf Z. Badros, MD, Jennifer Nishioka, PharmD, David Riedel, MD

Blood (2018) 132 (Supplement 1): 2085.

https://doi.org/10.1182/blood-2018-99-110887

Published: 2018

Journal Articles

Pre-Transplant Low Dose Cyclophosphamide Enhances Engraftment and Immune Reconstitution in Haploidentical Hematopoietic Stem Cell Transplant (HCT) Recipients Receiving Total Body Radiation (TBI) Free Reduced Intensity Conditioning with Post- Transplant Cyclophosphamide (PTCY)

Yasser Khaled, MD, George Yaghmour, MD, Christy R Parks, FNP, Deborah Lamontagne, MLS(ASCP)CM, Joshua Boss, RN, Diwura Owolabi, PharmD, BCOP, Sallyanne C. Fossey, PhD, Lisa Murphy, MT(ASCP), Robert Bradley, MD

Blood (2016) 128 (22): 3431.

https://doi.org/10.1182/blood.V128.22.3431.3431

Published: 2016

Journal Articles

Clinical Efficacy of BK Virus Specific T-Cells in Treatment of Severe Refractory Hemorrhagic Cystitis after HLA Haploidentical Transplantation

Oscar M. Pello, Anne Bradshaw, Andrew Innes, Sally-Anne Finn, Emma Bray, Shab Uddin, Eduardo Olavarria, Jane F. Apperley, MD, Jiří Pavlů

Blood (2016) 128 (22): 5726.

https://doi.org/10.1182/blood.V128.22.5726.5726

Published: 2016

Journal Articles

Myeloablative Conditioning With PBSC Grafts For T-Replete Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide Results In Universal Engraftment, Low Rates Of Gvhd, NRM and Excellent Survival Outcomes: An Analysis Of Two Consecutive Phase II Studies From a Single Center

Scott R. Solomon, MD, Stephanie Jacobson, FNP-C, OCN, Melissa Sanacore, PharmD, Xu Zhang, PhD, Connie Sizemore, Pharm.D., Stacy Brown, B.A., H. Kent Holland, MD, Lawrence E. Morris, MD, Asad Bashey, MD, PhD

Blood (2013) 122 (21): 3351.

https://doi.org/10.1182/blood.V122.21.3351.3351

Published: 2013

Journal Articles

BK Virus Disease Following Allogeneic Stem Cell Transplantation: A Cohort Analysis

Nienke MG Rorije, Margaret M Shea, Gowri Satyanarayana, MD, Sarah P Hammond, MD, Vincent T Ho, MD, Lindsey R Baden, MD, Joseph H Antin, MD, Robert J Soiffer, MD, Francisco M Marty, MD

Blood (2012) 120 (21): 1927.

https://doi.org/10.1182/blood.V120.21.1927.1927

Published: 2012

Journal Articles

Haploidentical Transplantation Using T-Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors Is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of A Prospective Phase II Trial

Connie A. Sizemore, PharmD, Asad Bashey, MD, PhD, Melissa Sanacore, PharmD, Karen Manion, RN, H. Kent Holland, MD, Lawrence E. Morris, MD, Stacey Brown, B.A., Xu Zhang, PhD, Scott R. Solomon, MD

Blood (2011) 118 (21): 889.

https://doi.org/10.1182/blood.V118.21.889.889

Published: 2011

Journal Articles

Defining Treatment Paradigms for BK Virus-Induced Hemorrhagic Cystitis in the Post-Allogeneic Hematopoietic Stem Cell Transplant Setting

Devi D Morrison, Samith Thomas Kochuparambil, David Deremer, Ethan Speir, Kristen Sterling, Meghan Sterrett, Vamsi Kota, MBBS, Anand P. Jillella, MD, Farrukh T Awan, MD, MS

Blood (2011) 118 (21): 4468.

https://doi.org/10.1182/blood.V118.21.4468.4468

Published: 2011

Journal Articles

The Characteristics of Hemorrhagic Cystitis After Allogeneic Stem Cell Transplantation, and Possible Predictive Value of Absolute Lymphocyte Count for Clinical Outcome.

Seung-Ah Yahng, MD, Byung-Sik Cho, MD, Sung-Eun Lee, MD, Ki-Seong Eom, MD, Yoo-Jin Kim, MD, Hee-Je Kim, MD, Seok Lee, MD, Chang-Ki Min, MD, Seok-Goo Cho, MD, Dong-Wook Kim, MD, Jong-Wook Lee, MD, Woo-Sung Min, MD, Chong-Won Park, MD

Blood (2010) 116 (21): 1284.

https://doi.org/10.1182/blood.V116.21.1284.1284

Published: 2010

Journal Articles

Weekly High-Dose Cidofovir Is an Effective Treatment for Symptomatic BK Virus (BKV)-Associated Hemorrhagic Cystitis (HC) after Allogeneic Stem Cell Transplantation (Allo-SCT).

Ioannis Baltathakis, MD, Michael Michael, MD, Eirini Grispou, PHD, Georgia Kourti, MD, Maria Bouzani, MD, Maria Anagnostopoulou, MD, John Apostolidis, MD, Dimitrios Karakassis, MD, Nicholas Harhalakis, MD, Olga Paniara, MD, Emmanuel Nikiforakis, MD

Blood (2006) 108 (11): 5306.

https://doi.org/10.1182/blood.V108.11.5306.5306

Published: 2006

Journal Articles

Immune Ablation Using High-Dose Cyclophosphamide without Stem Cell Rescue for Intractable Multiple Sclerosis.

Jamile Shammo, MD, Stacey E. Ban, MD, George Katsamakis, MD, Dusan Stefoski, MD, Michael Ko, MD, Carlene Porter, RN, NP, Sharon Manson, RN, NP, Stephanie A. Gregory, MD

Blood (2005) 106 (11): 5504.

https://doi.org/10.1182/blood.V106.11.5504.5504

Published: 2005

Journal Articles

Pilot Study to Test the Efficacy and Safety of Recombinant Factor VIIa (rFVIIa, NovoSeven™) in the Treatment of Refractory Hemorrhagic Cystitis Following High Dose Chemotherapy.

Aneel A. Ashrani, MD, Don A. Gabriel, MD, James L. Gajewski, MD, Nigel S. Key, MD

Blood (2004) 104 (11): 1136.

https://doi.org/10.1182/blood.V104.11.1136.1136

Published: 2004

Journal Articles

Holmium-166 ( 166 Ho)-DOTMP Skeletal Targeted Radiotherapy (STR ™ ) with Melphalan and Autologous Peripheral Stem Cell Transplant (PBSCT) for Multiple Myeloma (MM).

Mark Goodman, M.D., William I. Bensinger, M.D., Sergio Giralt, M.D, Donna Salzman, M.D., Katherine L. Ruffner, M.D., Hazel B. Breitz, M.D.

Blood (2004) 104 (11): 922.

https://doi.org/10.1182/blood.V104.11.922.922

Published: 2004

Journal Articles

166 Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials

Sergio Giralt, William Bensinger, Mark Goodman, Donald Podoloff, Janet Eary, Richard Wendt, Raymond Alexanian, Donna Weber, David Maloney, Leona Holmberg, Joseph Rajandran, Hazel Breitz, Richard Ghalie, Richard Champlin

Blood (2003) 102 (7): 2684–2691.

https://doi.org/10.1182/blood-2002-10-3250

Published: 2003

NARROW

Risk Factors and Different Therapeutic Patterns of Late-Onset Hemorrhagic Cystitis after Haploidentical Allogeneic Stem Cell Transplantation

Risk Factors of BK Virus Cystitis in Haematopoietic Stem Cell Transplantation-a Retrospective Monocentric Study

Intravesicular Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis (BKV-HC) Following Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Pre-Transplant Low Dose Cyclophosphamide Enhances Engraftment and Immune Reconstitution in Haploidentical Hematopoietic Stem Cell Transplant (HCT) Recipients Receiving Total Body Radiation (TBI) Free Reduced Intensity Conditioning with Post- Transplant Cyclophosphamide (PTCY)

Clinical Efficacy of BK Virus Specific T-Cells in Treatment of Severe Refractory Hemorrhagic Cystitis after HLA Haploidentical Transplantation

BK Virus Disease Following Allogeneic Stem Cell Transplantation: A Cohort Analysis

Haploidentical Transplantation Using T-Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors Is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of A Prospective Phase II Trial

Defining Treatment Paradigms for BK Virus-Induced Hemorrhagic Cystitis in the Post-Allogeneic Hematopoietic Stem Cell Transplant Setting

The Characteristics of Hemorrhagic Cystitis After Allogeneic Stem Cell Transplantation, and Possible Predictive Value of Absolute Lymphocyte Count for Clinical Outcome.

Weekly High-Dose Cidofovir Is an Effective Treatment for Symptomatic BK Virus (BKV)-Associated Hemorrhagic Cystitis (HC) after Allogeneic Stem Cell Transplantation (Allo-SCT).

Immune Ablation Using High-Dose Cyclophosphamide without Stem Cell Rescue for Intractable Multiple Sclerosis.

Pilot Study to Test the Efficacy and Safety of Recombinant Factor VIIa (rFVIIa, NovoSeven™) in the Treatment of Refractory Hemorrhagic Cystitis Following High Dose Chemotherapy.

Holmium-166 ( 166 Ho)-DOTMP Skeletal Targeted Radiotherapy (STR ™ ) with Melphalan and Autologous Peripheral Stem Cell Transplant (PBSCT) for Multiple Myeloma (MM).

166 Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only